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More than 20 years ago, the first genetically modified (GM) plants entered the seed
market. The patents covering the first GM plants have begun to expire and these can
now be considered as Off-Patent Events. Here we describe the challenges that will
be faced by a Secondary Party by further use and development of these Off-Patent
Events. Indeed, the conditions for Off-Patent Events are not available yet to form the
basis for a new viable industry similar to the generic manufacturers of agrochemicals
or pharmaceutical products, primarily because of (i) unharmonized global regulatory
requirements for GM organisms, (ii) inaccessibility of regulatory submissions and data,
and (iii) potential difficulties to obtain seeds and genetic material of the unique genotypes
used to generate regulatory data. We propose certain adaptations by comparing
what has been done in the agrochemical and pharmaceutical markets to facilitate the
development of generics. Finally, we present opportunities that still exist for further
development of Off-Patent Events in collaboration with Proprietary Regulatory Property
Holders in emerging markets, provided (i) various countries approve these events without
additional regulatory burdens (i.e., acceptance of the concept of data transportability),
and (ii) local breeders agree to meet product stewardship requirements.
Keywords: off-patent event, generic, transgenic, GMO, data transportability, emerging markets
INTRODUCTION
The first genetically modified (GM) plants were produced early in the 1980s by means of
Agrobacterium tumefaciens as a vector to introduce a new gene into the plant as a trait of interest
(Bevan et al., 1983; Herrera-Estrella et al., 1983). Numerous laboratories from the public and private
sectors have worked on the production of GM plants, leading to the first commercial GM plants
in the mid-1990s (James and Krattiger, 1996). Since then, many new GM crops have reached the
market and been adopted all over the world. In 2016, more than 18 million farmers grew GM crops
on a total of 185.1 million hectares in 26 countries, a 110-fold increase since the first releases (James,
2016), demonstrating the very successful adoption in global cropping systems despite intense
societal debates. The main traits commercialized are herbicide tolerance and/or insect resistance
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(James, 2016). More than 20 years after the initial
commercialization, patents covering these profit-making
Events have begun to expire. These patents were valid for 20
years after granting in the USA and Canada and after filing in
other countries. In contrast to generic product development in
the pharmaceutical and agrochemical industries, the current
regulatory regimes for GM crops make it particularly challenging
and currently virtually impossible to establish a viable generic
industry in this sector.
The timeline for commercialization of an Event is long (∼14
years for the first commercial launch) (Fraley, 2015) and the
investment high (McDougall, 2011), in particular to comply
with all the regulatory requirements, address the stewardship
expectations, and assume the liabilities associated with GM
crops, thereby reducing the market opportunities to only a few
companies for limited crop/trait combinations.
Proprietary Regulatory Property (PRP) Holders must
maintain regulatory approvals in the countries in which
they intend to release Events for cultivation as well as in
countries where plants containing the Event or the GM
plant-derived products will be exported. In many countries,
such approvals are limited in time and need to be renewed
regularly. PRP Holders must also observe stewardship
requirements and remain legally responsible for all issues
related to product identity, quality, and performance.
When the Event becomes off-patent, these requirements
remain in force if the PRP Holder wishes to maintain the
sales or if a Secondary Party wishes to commercialize the
Event. Jefferson et al. (2015) provided insights into some
of the challenges to be addressed in post-patent use of GM
crops.
Here we discuss the difficulties faced by any potential
Secondary Party who wishes to use or further develop
these Off-Patent Events, among which are (i) lack of
harmonization of the global regulatory requirements for
GM crops, (ii) limited accessibility to regulatory submissions
and data, and (iii) potential obstacles to obtain material of
the unique Event upon which the regulatory dossier was
created. Notwithstanding this problematic context, we present
existing opportunities to further develop Off-Patent Event
plants in collaboration with PRP Holders in new markets,
provided that the concept of data transportability becomes
widely accepted and that the product stewardship and the
regulatory requirements are observed by all users at the global
level.
We will not cover the generation of a Generic Event (see
Glossary) that differs from an Off-Patent Event (see Glossary).
The development of a Generic Event requires a complete
regulatory package, even when some data on specific components
of the Event can be obtained from the PRP Holder or are publicly
available. Recently, an approach has been reported to produce
generic glyphosate-tolerant soybean (Glycine max) (Rojas Arias
et al., 2017). Regulatory and stewardship responsibilities for a
Generic Event will be the same as for an Off-Patent Event and
this will also be true for the liabilities that could be even more
challenging for the developer of a Generic Event, which will
probably be unpatentable.
OFF-PATENT EVENTS ARE NOT GENERIC
Generic products are widespread in the pharmaceutical or
agrochemical industries because of the specific legislation that
facilitates their commercialization. In these agrochemical or
pharmaceutical products, the off-patent active ingredient is
a molecule or a protein (“biosimilar”) and is the same (or
“similar” for a protein) as in the original product, even when
the production process is different. In addition, the formulation
of the active ingredient can have been modified (Alfonso-
Cristancho et al., 2015). Although specific procedures were
developed to facilitate the registration of generic or biosimilar
products (such as possibilities for data bridging in regulatory
applications and authorization to initiate a regulatory package of
a product before expiration of the corresponding patent), generic
products have to obtain their own commercial authorizations.
In the case of GM plants, the situation differs, because the
intellectual property coverage does not protect a molecule or a
protein, but an Event, and no legislation has yet been put in
place in any country to facilitate the conditions for development,
sale, and use of Off-Patent Events. Below, we will focus on the
challenges to be faced by any Secondary Party wishing to further
develop and use an Off-Patent Event.
INTELLECTUAL PROPERTY RIGHTS
An Event can be protected by several patents, covering,
for instance, the DNA sequences used (promoter, coding
sequence,. . . ) to obtain the new trait, the technologies used to
produce the Event, the Event itself, its use, and the specific
detection tests used to identify its presence. Ten patents cover
the soybean Event GTS-40-3-2 in the USA (Jefferson et al., 2015).
When ascertaining that an Event is off-patent, one has to check
the expiration of all the patents in the considered countries, i.e.,
countries for cultivation and for import, that cover the Event
itself, its use, and its derived products. Indeed, one should take
into account that the commercialized Event may not be patented
as such, but any plant containing the construct for the trait and
that, hence, the patent concerning the plant would also cover the
commercial Event.
Even when an Event is off-patent, the commercial varieties
derived from this Event may still be protected, either through
a patent in the USA or through the Plant Variety Protection
(PVP) Act in most other countries. In the USA, patented varieties
cannot be used for breeding, whereas in Europe, for example, it
is allowed to breed varieties under PVP. In this latter case, the
derived varieties can be freely commercialized if the patented trait
has been removed. However, if the trait is still patented, a license
from the patent trait owner is necessary for as long as that patent
is in force.
Let’s assume that the Event and its derived varieties are
completely off-patent, then the PRP Holder would be confronted
by the situation in which unlicensed Secondary Parties could
use the Off-Patent Event for breeding (for instance, to develop
new varieties) and cultivation (for instance via farm-saved seeds).
An unlicensed Secondary Party could possibly also utilize the
Off-Patent Event to generate varieties with combined traits
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(i.e., “stacked” Events), but, in that case, the Secondary Party
would require the necessary technical ability and possess the
PRP-related information to fulfill the regulatory conditions for
such stacked Events. Potential candidates would include seed
companies experienced in developing and managing Events,
public institutions capable of creating their own varieties under
license from the PRP Holder (such as the University of Arkansas)
(Miller, 2016), and individual farmers able to grow farm-saved
seeds, provided again no previously signed technology use
agreement exists with the PRP Holder that prohibits saving seeds
for subsequent cultivation and that local legislation and licenses
allow its application to purchased seed bags. In contrast, licensed
seed companies are required to use the Event only in accordance
with the terms of their license agreement that usually contain
restrictions on its use, independently of the patent coverage, and
generally, such restrictions survive the termination or expiration
of the license agreement. In other words, an Off-Patent Event
cannot be used in a manner that is not permitted by the license
terms. The same terms would apply also to farmers who have
signed a technology use agreement with the PRP Holder.
Thus, as the intellectual property rights of the Event and its
derived varieties expire, the PRP Holder has to reconsider the
value capture mechanisms and decide in due time on possible
options: (i) continue the commercialization on its own and/or
reach an agreement with Secondary Parties interested in the use
of the Off-Patent Event, or (ii) discontinue sales and regulatory
approvals. In this decision process, the market opportunity will
be considered for stacked Events, in which the Off-Patent Event is
combined via breeding with other Events, possibly still protected
by intellectual property rights. Such combinations may allow
novel applications of the Off-Patent Event.
Should a Secondary Party wish to develop, market, or use an
Off-Patent Event independently from the PRP Holder, aspects
related to the material, the regulatory requirements, and the
stewardship should be taken into account.
REPRESENTATIVE PLANT MATERIAL OF
THE OFF-PATENT EVENT
A Secondary Party interested in the use of an Off-Patent Event
must first obtain legal access to the Event. If the Event itself has
been patented, then seeds have generally been deposited in an
International Depository Authority (IDA) under the Budapest
treaty (WIPO, 2018), such as the American Type Culture
Collection (ATCC) in the USA or the National Collections of
Industrial, Food and Marine Bacteria (NCIMB) in the UK.
After patent issuance, such deposited biological material must
be made freely available to the public. The storage time in
an IDA is at least 30 years (WIPO, 2002). However, a sample
requested during the patent validity may not be used by the
purchaser for any commercial use, because it would constitute
a patent infringement. Moreover, under the ATCC Material
Transfer Agreement, ATCC Material and Progeny “may only
be used by the Purchaser’s Investigator for research purposes
and only in the Investigator’s laboratory”—“Any commercial
use of the Biological Material is strictly prohibited without the
ATCC prior written consent” (Davis, 2011). Notwithstanding and
independently of the ATCC restriction, under paragraph 5 of the
Generic Event Marketability and Access Agreement (GEMAA),
as amended on November 5 2015, PRP Holders agree to make
the Event available to the GEMAA signatories (GEMAA, 2015).
REGULATORY STRATEGY
At the time an Event becomes Off-Patent in the major
agricultural markets, the PRPHolder will have developed a global
data package and obtained approvals for commercialization in
countries in which the GM crop is intended for cultivation
and for export in countries in which the harvested Event-
containing plants, parts or GM plant-derived products will
be imported. In the case of the United States Department
of Agriculture-Animal and Plant Health Inspection Service
(USDA-APHIS), once an Event is deregulated, it is considered
equivalent to any other free article without need for follow-
up submissions, unless data emerge that significantly change
the risk assessment. In contrast to the USDA, in many other
countries such as China, the EU, and South Korea, approvals
are limited in time and resubmissions must be scheduled to
renew approvals and avoid costly disruptions of international
commodity trade. A resubmission may be a formal request for
extension, but most authorities require additional information
accounting for the acquired knowledge and even updates of
previous studies to meet redefined needs since the original
approval. A third type of approval (such as the procedures of
the United States Environmental Protection Agency [US EPA]
for Plant Incorporated Protectants) is even more restrictive:
similar to chemical crop protection products, it is conditional,
i.e., an approval will have mandatory performance and reporting
obligations, such as implementation of an insect resistance
management plan, and is granted directly to one particular
party. In addition, such an EPA approval may be provisional.
The distinction between the different types of approvals is
important when the consequences of the off-patent situation are
evaluated.
Although the PRP Holder will probably not stop supporting
the regulatory approvals for the Off-Patent Events abruptly, no
continuation will be guaranteed, especially if the PRP Holder
intends to replace the Off-Patent Event with an improved
patented Event. Thus, to be able to develop, breed, or use the Off-
Patent Event, any Secondary Party must ensure that the necessary
permits are and remain in place.
For a USDA-APHIS deregulation, there is no need to request
a second deregulation. For time-limited approvals, the Secondary
Party should monitor whether the approvals have been, or are
in the process of being, renewed by the Primary PRP Holder.
When approvals expire in a given country, the Secondary Party
will have to cease any unapproved use in that country or obtain
new approvals. Alternatively, the Secondary Party could apply for
its own authorizations, possibly the only option in administrative
systems that provide party-dependent authorizations (such as
the US EPA), but associated with high regulatory costs due to
compilation, submission, and maintenance of the authorization
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and resulting in obligations for and liability of the Secondary
Party.
In contrast to usually publicly available approvals, the
PRP submissions are subject to confidentiality claims and are
protected internationally under Article 21 of the Cartagena
Protocol on Biosafety (Secretariat of the Convention on
Biological Diversity, 2000) as well as possibly covered by
copyright claims. The fact that some information is publicly
available does not imply that it can be used to support a Second
Party’s own regulatory package or own application. For instance,
in Europe, the regulatory system provides data protection
to applicants, because Regulation 1829/2003/EU (Article 31)
foresees that parties cannot use or refer to data submitted by
the initial applicant in their application for 10 years, and under
Directive 2001/18/EC (Article 25) the prohibition is unlimited in
time.
In view of the difficulties for Secondary Parties to renew a
particular approval (e.g., in China, South Korea, and the EU),
it is very unlikely that Secondary Parties will have access to up-
to-date information, because the data protection period starts
from the submission date of specific information; in other words,
Secondary Parties will not be allowed to use new information
submitted as part of a resubmission until expiration of the
protection period relevant for the renewal. However, if it is
practically impossible and too expensive to establish its own
complete safety package, a Secondary Party has always the
possibility to negotiate access to submitted information with the
PRP Holder.
SAFETY DATA PACKAGE
The GM Event safety is supported by a data package comprising
studies explicitly providing information required by the decision
makers. Whereas some information may be general, relevant to
the trait (such as herbicide tolerance or insect resistance) or
the gene (such as origin and nature of the nucleotide sequence
and the corresponding protein) and be valid for several Events;
most data, such as, for instance, the nucleotide sequence at
the insertion site, the effect of the insertion on agronomical
parameters, or the biological composition, are specific for each
Event. In this case, it is important to demonstrate that the
stud(y)(ies) has(ve) been conducted on the specific Event and
molecular data and/or information on the genealogy of the
material in support of the claims may be required by the
authorities. The PRP Holder usually owns the study protocols
and reports, and even when submitted as part of a data package,
some level of protection may prevail or certain information may
remain inaccessible due to confidentiality or copyright claims.
Whereas an initial data package serves to support market
introduction, during the commercial lifetime of a GM crop
additional data is accumulated and the data package is expanded.
First of all, because the data package is submitted in various
countries, the locally competent authorities may need specific
data, requiring repetition of the initial study with an adapted
study design or a completely new study. The PRP Holder
can usually anticipate most requests for an acceptable study
report but the problems expand when a country requires
studies performed in situ. Secondly, over time, requirements
change and are redefined, creating difficulties when a time-
limited authorization expires and the authorities demand the
submission of an up-to-date study design as part of the renewal.
Finally, during large-scale implementation, unexpected findings
might emerge that necessitate a specific effort to understand
the discovery source and the impact on the risk assessment. In
conclusion, the safety data package has to be substantially and
continuously maintained throughout the life cycle of the Event,
independently of its patent life. When a Secondary Party wants to
independently engage in the use of an Off-Patent Event, a safety
data package must be established as follows:
- by referring to the publicly available studies or data previously
submitted by the PRP Holder, but usually not encompassing
the entire safety package and,thus, rarely sufficient; indeed, the
PRP Holder may have recently obtained information that has
not been supplied to the competent authorities yet and, hence,
are unknown and cannot be used by the Secondary Party;
- by agreeing with the PRP Holder on conditions for access to
and use of the existing data;
- by establishing a proprietary data package by repeating the
patented studies, requiring access to the biological material
contained in the Off-Patent Event and legal permission to use
such material for regulatory purposes. Under the current laws,
at least in the USA, this data package can be initiated only
when the Event or its constituents are off-patent.
COMPLIANCE WITH APPROVAL
CONDITIONS
An additional regulatory aspect relates to the conditions and
liabilities associated with the approval. Depending on the type
of Event and its approval, specific stipulations may be imposed.
The PRP Holder is responsible for ensuring that all specifications
are implemented, possibly by transferring part of its obligations
to licensees, including farmers, via contracts and technology
use agreements. For example, specific labeling of the (Event-
containing) GM products may be mandatory to inform the
farmers about the nature of the material or about particular
management practices. In some cases, the implementation of
an insect resistance management plan is a prerequisite for
the approval. These examples illustrate that the regulatory
obligations of the PRP Holder do not stop at the approval, but
need to be maintained rigorously during the lifetime of the Event.
Upon patent expiry, the leverage of the PRP Holder over
other users is in principle reduced. Facing continuous and
onerous regulatory obligations, but less well equipped to impose
conditions, the PRP Holder will re-evaluate whether to comply
with the regulatory requirements. In addition, when Secondary
Parties will supply the same material as a new source, there is a
risk that they may not comply with all the regulations imposed
on the PRP Holder. More importantly, in the case of non-
compliance or any unexpected finding, the PRP Holder will be
the first to be questioned and from whom liability and redress
will be sought. Therefore, the incentives for a PRP Holder to
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discontinue sales and regulatory support for an Off-Patent Event
and provide a new, patented Event as a substitute are extremely
high.
PRODUCT STEWARDSHIP
Product Stewardship is the responsible management of a
product from its launching through its use to its ultimate
discontinuation. Although safety and compliance with legal
obligations are inherent conditions to be observed, stewardship
covers additional aspects of identity, purity, quality, and
performance of GM crops and imposes a quality management
system covering all Event handling that is subject to external
audits. Furthermore, PRP Holders are expected to ensure the
use of their products in a manner that respects the supply
chain and does not disrupt international trade. The “Excellence
Through Stewardship” (ETS) initiative was established by the
biotechnology industry on a voluntary basis and promotes the
adoption of stewardship programs and quality management
systems across the full biotechnology plant product life
cycle (www.excellencethroughstewardship.org). From this
comprehensive stewardship program, some elements are
particularly relevant for the discussion on Off-Patent Events.
To avoid trade disruption, the developers (PRP holders) must
ascertain that all required regulatory permits and authorizations
are available in countries in which they intend to commercialize
the Off-Patent Event and any derived products. For seed
production, special care is taken to ensure the traceability and
to avoid intermingling between non-GM and GM seed, as well
as between different GM Events, requiring detailed knowledge
of Event performance and characteristics, such as identity,
genetic purity, and performance criteria. Along the value chain
of the product, downstream users, i.e., farmers and downstream
processing, need to be informed and trained for the optimal
utilization of the Event, e.g., agricultural practices, labeling,
channeling, and identity preservation. A specific case is the
Integrated Pest Management (IPM) that aims at minimizing
damage of pests, such as weeds, insects, and viruses, and
maximizing the availability and longevity of the tools needed
for the pest management. Irrespective of the impositions by
the authorities, stewardship requires the developers to create
their own IPM approach during the Research & Development
phase, such as design of refuges of non-GM crops amidst GM
insect-resistant crops. Due to the complexity of the process and
the potential impact on multiple stakeholders, establishment of
an Incident Response System is an essential part of any quality
management system and is put in place as early as possible.
Examples of incidents include improper functioning of the trait,
an unintended, unauthorized release of the plant material in the
environment, or a seed quality failure. Finally, developers must
anticipate product discontinuation, as, for instance, when the
commercial interest in a trait or particular Event has diminished
and does not justify regulatory support continuation, implying a
managing process to remove the specific Event from the market.
Any Secondary Party willing to further develop an Off-Patent
Event will have to establish a stewardship program for the
different development and commercialization steps of the Off-
Patent Event. For practical purposes, in the USA, in view of the
conditions imposed in article 13(a) of the GEMAA (GEMAA,
2015), the Secondary Party will have to become an ETS member
and accept to be regularly externally audited. In addition, when
such developments are done in collaboration with the PRP
Holder, this PRP Holder may oblige the Secondary Party to have
an audit system comparable to ETS.
THE PRECEDENT OF THE AGACCORD
To date, only the USA (through a voluntary, industry-negotiated
agreement) established a framework agreement to manage
Off-Patent Events, designated the AgAccord (www.agaccord.
org). This framework comprises two separate agreements that
cover the full spectrum of issues related to patent expiration:
the GEMAASM (GEMAA, 2015) and the Data Use and
Compensation Agreement (DUCA). The AgAccord supports
business opportunities for parties seeking to use Off-Patent
Events in the USA, while ensuring that all global regulatory
commitments are maintained for Off-Patent Events and that
the USA exports of the event-containing products are not
disrupted. The AgAccord establishes a standard process to make
available Off-Patent Events and the corresponding proprietary
regulatory information otherwise not accessible to interested
parties. In addition, this access begins prior to the patent
expiration. However, the PRP Holder may choose to maintain all
necessary authorizations and, thus, not exchange information or
material. Although these agreements apply to the USA only, they
constitute a starting point for the types of obligations that would
be expected between a Secondary Party outside the USA and the
PRP Holder, in particular in the area of stewardship.
MARKET OPTIONS AND EXAMPLES OF
OFF-PATENT UTILIZATION
In the case of the original glyphosate-tolerant Roundup Ready
soybean Event, known as GTS 40-3-2, prior to the GEMAA
instatement, Monsanto indicated its willingness to maintain full
global regulatory support until 2021. Now that GEMAA is active,
if Monsanto wants to discontinue the regulatory responsibilities
for GTS 40-3-2, it needs to notify all interested parties at least 7
years prior to any such discontinuation. In such a notification,
Monsanto, as PRP holder must set forth (i) the discontinuation
date and (ii) whether it will retain or transfer the PRP ownership
(GEMAA, 2015). In case of discontinuation, it has to announce
the last sale. As Monsanto is commercializing a replacement
Event for GTS 40-3-2, this Event will logically be discontinued
in the future.
After patent expiration, new utilizations may be released
for the Off-Patent Event, including for instance saving and
replanting seeds of certain varieties in the fields by farmers,
provided the originally purchased seeds are not covered by
other patents or use restrictions in the seed bag license or in a
technology use agreement. Since November 2014, such a use of
GTS-40-3-2 has been possible: the University of Arkansas System
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Division of Agriculture released a glyphosate-tolerant soybean
varieties UA 5414RR in December 2014 and UA 5715GT in April
2016, both available for sale to USA farmers without technology
fees and without restrictions on farmer-saved seed (Miller, 2016).
Thanks to a specific license from Monsanto, breeding material
has been provided to public farmers, including the University of
Arkansas (Miller, 2016).
In contrast, in April 2015, Event MON810 conferring insect
resistance in corn (Zea mays) also became off-patent (GEMAA,
2013), but, since 30 September 2015, its approval by the
US EPA as a corn product with a single plant-incorporated
protectant has expired and, therefore, cannot be freely used by
seed companies and farmers in the USA (U.S. Environmental
Protection Agency, 2010). The plant-incorporated protectant
in MON810, Bacillus thuringiensis Cry1Ab delta-endotoxin,
retains an approved status for the US EPA. In this case,
because the regulatory approvals for use as a single trait
have not been maintained by the PRP Holder after the USA
patent expiration, Secondary Parties in the USA have no direct
opportunity to exploit the potential of the patent expiration
without obtaining of a new permit. Following GTS-40-3-2 and
MON810, a handful of Events will also probably become off-
patent in the USA between 2014 and 2020, and several more after
2020.
These examples show that the possible use of Off-Patent
Events without a large investment in the regulatory package
remains very limited for Secondary Parties, because it strongly
depends on agreements with the PRP Holders to have access to
the Event and to keep approvals in force. Moreover, outside the
USA, a contractual framework, such as the AgAccord that would
facilitate possibilities for Secondary Parties, is lacking.
EMERGING MARKET OPTIONS AND
POTENTIAL DIRECTIONS FOR FURTHER
IMPROVEMENT
Many untapped opportunities remain for GM corn in emerging
markets: “in Asia, there are about 60 million hectares of potential
biotech maize, with 35 million hectares in China alone; there
is a similar potential in Africa for up to 35 million hectares of
biotech maize” (James, 2016). New GM corn markets in Africa
will probably include Nigeria, Ethiopia, Namibia, Swaziland, and
Malawi, and Vietnam in Asia. Secondary Parties will hopefully
appear in such markets to create new plant breeding and
commercial seed activities possibly in their own and the GM
maize PRP Holder interests. In these countries as in many
other African and South American countries, the patent status
of an Event that has been commercialized elsewhere for 20
years is not an issue, because in most of them the Events
have not been the subject of patent filings. Consequently, no
intellectual property right for the Event exists in these countries
and country-dependent patent rights are not extendable to
countries where no filing has been done. In many countries,
especially in Africa, the biosafety regulatory environment still
needs full implementation. In addition, workable seed laws,
variety certification procedures, and seed certification schemes
are not regionally harmonized and effective, with negative
outcomes for breeding investments and for the emergence
of professionally certified seed production and reliable seed
supplies.
Even if conditions existed favoring the emergence of local
and professional seed companies, the African countries willing
to regulate the cultivation of GM crops would need to
accept the concept of data transportability to facilitate such
a development: in agreement with the PRP Holder, data
packages establishing the human and environmental safety of
the Off-Patent Event agreed in experienced countries, such
as South Africa, should be recognized as acceptable in other
African countries. In this manner, risk assessment could be
focused on studies that analyze the efficacy and environmental
impact of the trait under local conditions. When countries
have similar growing conditions and pests, data transportability
can also apply to field data (Garcia-Alonso et al., 2014).
With enhanced internationally harmonized regulatory systems,
emerging markets may become the best place for non-
conflicting collaborations between PRP Holders and Secondary
Parties.
In addition, in the presence of a political willingness,
the development of a generic industry for GM crops could
be stimulated by initiatives, such as those developed in
the pharmaceutical industry following the USA Drug Price
Competition and Patent Term Restoration Act (Public Law
98-417). According to this research or safe harbor exemption,
performing research and tests for the preparation of regulatory
approvals does not constitute infringement for a limited term
before the end of the patent term. This exemption allows
manufacturers to prepare generic drugs in advance of the patent
expiration. In the European Union, equivalent exemptions are
allowed.
CONCLUSION
Off-Patent Events for GM crops are and will increasingly
become a reality, constituting a major challenge for PRP
Holders. By maintaining authorizations, they remain
responsible and liable for stewardship and have to keep
data updated for regulatory compliance purposes, which is
difficult when Secondary Parties use the Off-Patent Event.
Although Off-Patent Events utilized as single Events might be
scarce, they might be used in combinations with additional
traits.
Currently, the GM crop regulatory systems do not facilitate
a generic industry for Off-Patent Events. GM regulatory
harmonization and simplification, including the acceptance of
data transportability among countries and regions, would be a
significant achievement for increased use and acceptance of the
technology. Such improvements would allow a cost reduction
and potentially open the market to new actors, in addition to the
few multinationals that currently have the resources to develop
and maintain GM Events.
Initiatives, such as the AgAccord are essential to
facilitate the further development of Off-Patent Events.
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The founding members of the AgAccord could seemingly
decide to extend the agreement territory to the rest of
the world, without adverse impact on the members, but
with many new opportunities for non-USA signatories.
As mentioned above, improvements can also be made by
taking advantage of the applications in the pharmaceutical
industry to speed up the development of generic
drugs.
Although emerging markets often still lack a regulatory
environment that would allow the commercialization of GM
crops, the most promising opportunities for Secondary Parties in
direct collaboration with PRP Holders may reside in the African
and Asian countries that are in the process of setting up a
regulatory framework to handle GM crops for scientific research
and for commercialization.
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GLOSSARY
Event: the unique recombinant DNA insertion event that took
place in one plant cell, which was then used to generate a
transgenic plant. The selected Event is used for breeding and
development of commercial varieties in a crop.
generic: as used here, refers to a product that is not protected by
intellectual property rights and that is freely available for use by
third parties for commercial and development purposes.
Generic Event: an Event that harbors the same inserted genetic
sequences as the corresponding commercialized Event, but that
is made de novo with nucleotide sequences and technologies
available in the public domain.
Off-Patent Event: an existing Event, originally patented
by, and commercially available through, a PRP Holder
for which the patent protection has expired in a specific
territory.
Proprietary Regulatory Property (PRP): The data, dossiers,
and authorizations that enable the cultivation and sale of
an Event in any countr(y)(ies) in which it is approved
for cultivation and allow the importation and use of
material containing that Event (seed product, grain,
or any product thereof regulated as a result of the
Event).
Proprietary Regulatory Property (PRP)Holder: an entity that owns
or controls the PRP and any other relevant intellectual property
rights for an Off-Patent Event.
Secondary Party: an entity that further develops or uses an Off-
Patent Event.
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